L2Capital Deep research, on demand
Login Register
AMPH logo

AMPH · Amphastar Pharmaceuticals, Inc.

Last updated Oct 19, 2026
Recommendation
BUY
12-Month Target
$36.00
+38.0% return
Reference Price
$26.08
October 19, 2026
Download PDF Read HTML
INSTITUTIONAL MEMORANDUM · AMPH

Can Compliance Risk Hide a Compounder?

FDA damage is priced as permanent while launches and buybacks rebuild per-share earnings.

L2 Capital Institutional Verdict

Amphastar Pharmaceuticals, Inc. (AMPH) is currently rated BUY with a 12-month valuation target of $36.00 (implied return: +38.0%). Based on forensic analysis of SEC filings and audited cash flows, Medium-High conviction reflects Second-quarter revenue rose 5% to $183.9 million and gross margin recovered to 50.8%, but glucagon revenue fell 42% and BAQSIMI declined 3%..

Executive Thesis

We rate Amphastar BUY with a $36 target because the market discounts its durable cash generation as if current regulatory and generic-pricing pressures were permanent. Vertical integration, technically difficult dosage forms, BAQSIMI, and a credible 2027 launch slate provide a differentiated earnings engine. The FDA warning letter, concentrated distribution, acquisition milestones, related-party transactions, and a 2028-2029 maturity wall prevent a high-conviction designation. Accumulate below $29, size conservatively, and require visible IMS remediation before moving to a full position.

Key Actionable Findings

Click any finding to interrogate with Andy ↗
Second-quarter revenue rose 5% to $183.9 million and gross margin recovered to 50.8%, but glucagon revenue fell 42% and BAQSIMI declined 3%.
Ipratropium contributed $8.4 million within one quarter of launch; insulin aspart and AMP-018 remain the principal 2027 commercial catalysts.
The IMS FDA warning letter is severe, while the $100 million BAQSIMI milestone and 2028-2029 debt maturities constrain otherwise strong cash generation.

Frequently Asked Questions: AMPH

What is L2 Capital's investment rating and price target for AMPH?

L2 Capital currently maintains an institutional rating of BUY on Amphastar Pharmaceuticals, Inc. (AMPH) with a 12-month target price of $36.00 (implied return: +38.0%), backed by Medium-High conviction.

What is the core investment thesis for AMPH?

We rate Amphastar BUY with a $36 target because the market discounts its durable cash generation as if current regulatory and generic-pricing pressures were permanent. Vertical integration, technically difficult dosage forms, BAQSIMI, and a credible 2027 launch slate provide a differentiated earnings engine. The FDA warning letter, concentrated distribution, acquisition milestones, related-party transactions, and a 2028-2029 maturity wall prevent a high-conviction designation. Accumulate below $29, size conservatively, and require visible IMS remediation before moving to a full position.

What are AMPH's latest audited financial fundamentals?

According to audited SEC EDGAR filings, Amphastar Pharmaceuticals, Inc. reported total revenue of $719.9M (-1.7% YoY), Gross Margin of 49.5%, Free Cash Flow of $121.2M, and Net Debt of -$170.2M.

What key risks and catalyst factors should investors monitor for AMPH?
  • Second-quarter revenue rose 5% to $183.9 million and gross margin recovered to 50.8%, but glucagon revenue fell 42% and BAQSIMI declined 3%.
  • Ipratropium contributed $8.4 million within one quarter of launch; insulin aspart and AMP-018 remain the principal 2027 commercial catalysts.
  • The IMS FDA warning letter is severe, while the $100 million BAQSIMI milestone and 2028-2029 debt maturities constrain otherwise strong cash generation.